Effective immediately, two CAR T-cell therapies require authorization for Medicare Advantage members
Effective immediately, the following CAR (chimeric antigen receptor) T-cell therapies require authorization for Blue Cross Medicare Plus BlueSM PPO and BCN AdvantageSM members:
HCPCS code | Brand name | Generic name |
---|---|---|
Q2041 | YescartaTM | axicabtagene ciloleucel |
Q2040 | KymriahTM | tisagenlecleucel |
To request authorization for these therapies:
Since these requests require thorough review, we ask that you request an expedited review only if the standard review time frame could place the member's health in serious jeopardy.
Posted: March 2018
Lines of business: Blue Cross Blue Shield of Michigan and Blue Care Network